Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin

Investigational New Drugs

Volumn 32, Issue 1, 2014, Pages 75-86

  Li, Zhao Hui ^a   Zhang, Qian ^a   Wang, Hai Bin ^b   Zhang, Ya Nan ^a   Ding, Ding ^a   Pan, Li Qiang ^a   Miao, David ^c   Xu, Shi ^a   Zhang, Chen ^a   Luo, Pei Hua ^a   Naranmandura, Hua ^a   Chen, Shu Qing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Zhejiang Hisun Pharmaceutical Co Ltd   (China)

^c Concortis Biosystems Corp ^*  (United States)

Author keywords

CD20; Conjugate; MMAE; Ofatumumab; Targeted therapy

Indexed keywords

AMINOBENZOATES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CELL LINE, TUMOR; ENDOCYTOSIS; HUMANS; LYMPHOMA, B-CELL; LYSOSOMES; MALE; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899092032     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9995-y     Document Type: Article

References (28)

1. Sioud M, Mobergslien A (2012) Selective killing of cancer cells by peptide-targeted delivery of an anti-microbial peptide. Biochem Pharmacol 84(9):1123-1132. doi:10.1016/j.bcp.2012.08.002
2. Goldmacher VS, Kovtun YV (2011) Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv 2(3):397-416
3. Stack GD, Walsh JJ (2012) Optimising the delivery of tubulin targeting agents through antibody conjugation. Pharm Res 29(11):2972-2984. doi:10.1007/s11095-012-0810-9
4. Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA (2012) Antibody-drug conjugates - a perfect synergy. Expert Opin Biol Ther 12(9):1191-1206. doi:10.1517/14712598.2012.693473
5. Tedder TF, Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15(9):450-454. doi:10.1016/0167-5699(94)90276-3 (Pubitemid 24272191)
6. Maloney DG (2005) Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 23(26):6421-6428. doi:10.1200/JCO.2005.06. 004
7. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8):2825-2833 (Pubitemid 28363048)
8. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, Valerius T, van de Winkel JG, Glennie MJ (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104(6):1793-1800. doi:10.1182/blood-2004-01-0039 (Pubitemid 39202289)
9. Cheson BD (2010) Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 28(21):3525-3530. doi:10.1200/JCO.2010.27.9836
10. Zhang B (2009) Ofatumumab. MAbs 1(4):326-331
11. Veliz M, Pinilla-Ibarz J (2011) Role of ofatumumab in treatment of chronic lymphocytic leukemia. J Blood Med 2:71-77. doi:10.2147/JBM.S13063
12. Dyer MJ (2012) Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. Ther Adv Hematol 3(4):199- 207. doi:10.1177/2040620712445329
13. Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, Handley FG, Ihle NC, Senter PD, Alley SC (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 16(5):1282-1290. doi:10.1021/bc050201y (Pubitemid 41368132)
14. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102(4):1458-1465. doi:10.1182/blood-2003-01-0039 (Pubitemid 36988057)
15. Han KY, Yang D, Chang EJ, Lee Y, Huang H, Sung SH, Lee ZH, Kim YC, Kim HH (2007) Inhibition of osteoclast differentiation and bone resorption by sauchinone. Biochem Pharmacol 74(6):911-923. doi:10.1016/j.bcp.2007.06.044 (Pubitemid 47212083)
16. Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer DL, Doronina SO, Siegall CB, Francisco JA, Senter PD, Wahl AF (2004) Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 10(23):7842-7851. doi:10.1158/1078-0432.CCR-04-1028 (Pubitemid 39587522)
17. Beekman JM, van der Poel CE, van der Linden JA, van den Berg DL, van den Berghe PV, van de Winkel JG, Leusen JH (2008) Filamin A stabilizes Fc gamma RI surface expression and prevents its lysosomal routing. J Immunol 180(6):3938-3945
18. Lv M, Lin Z, Qiao C, Gen S, Lang X, Li Y, Feng J, Shen B (2010) Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity. Cancer Lett 294(1):66-73. doi:10.1016/j.canlet.2010.01.023
19. Naranmandura H, Chen X, Tanaka M, Wang WW, Rehman K, Xu S, Chen Z, Chen SQ, Suzuki N (2012) Release of apoptotic cytochrome C from mitochondria by dimethylarsinous acid occurs through interaction with voltage-dependent anion channel in vitro. Toxicol Sci 128(1):137-146. doi:10.1093/toxsci/kfs154
20. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10(20):7063-7070. doi:10.1158/1078-0432.CCR-04-0789 (Pubitemid 39383058)
21. Sievers EL, Senter PD (2013) Antibody-drug conjugates in cancer therapy. Annu Rev Med 64:15-29. doi:10.1146/annurev-med-050311-201823
22. Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, Payne G, Steeves R, Whiteman KR, Widdison W, Xie H, Singh R, Chari RV, Lambert JM, Lutz RJ (2011) Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 22(4):717-727. doi:10.1021/bc100480a
23. Braslawsky GR, Kadow K, Knipe J, McGoff K, Edson M, Kaneko T, Greenfield RS (1991) Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity. Cancer Immunol Immunother 33(6):367-374
24. Goulet AC, Goldmacher VS, Lambert JM, Baron C, Roy DC, Kouassi E (1997) Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization. Blood 90(6):2364-2375 (Pubitemid 27392720)
25. Nightingale G (2011) Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. Ann Pharmacother 45(10):1248-1255. doi:10.1345/aph.1P780
26. Lin TS (2010) Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics Pers Med 3:51-59
27. Michel RB, Mattes MJ (2002) Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res 8(8):2701-2713 (Pubitemid 34856360)
28. Pettit GR (1997) The dolastatins. Fortschr Chem Org Naturst 70:1-79